Research & Development

How Will AI Transform Drug Discovery and Development in Biopharma?
Research & Development How Will AI Transform Drug Discovery and Development in Biopharma?

Artificial Intelligence (AI) has the potential to revolutionize drug discovery and development, offering numerous advantages that could transform current practices in the biopharmaceutical industry. By merging Accenture's advanced capabilities in AI scaling with the innovative ITO™ platform

Ryvu and nCage Partner to Innovate Antibody-Drug Conjugate Therapies
Research & Development Ryvu and nCage Partner to Innovate Antibody-Drug Conjugate Therapies

In a pioneering move to advance cancer treatment, Ryvu Therapeutics and nCage Therapeutics have announced a research collaboration aimed at developing a next-generation antibody-drug conjugate (ADC) platform. This partnership promises to leverage nCage's TRAP cage platform, a novel drug delivery

Biond and Merck KGaA Partner to Trial New Treatment for Solid Tumors
Research & Development Biond and Merck KGaA Partner to Trial New Treatment for Solid Tumors

Biond Biologics Ltd., a private biopharmaceutical company, has entered into a partnership with Merck KGaA, Darmstadt, Germany, to support a Phase 1 clinical trial aimed at treating patients with unresectable or metastatic solid tumors. This clinical trial, designated as BND-35-001 (NCT06274437),

How Does ROXYBOND Fight Opioid Abuse and Ensure Pain Relief?
Research & Development How Does ROXYBOND Fight Opioid Abuse and Ensure Pain Relief?

The recent FDA approval of Protega Pharmaceuticals Inc.'s ROXYBOND (oxycodone hydrochloride) immediate-release (IR) CII 10 mg tablet marks a significant milestone in managing severe pain where alternative treatments fall short. ROXYBOND 10 mg stands out as the first FDA-approved abuse-deterrent IR

How Will Novartis and Monte Rosa Advance MRT-6160 in Immune Therapies?
Research & Development How Will Novartis and Monte Rosa Advance MRT-6160 in Immune Therapies?

Monte Rosa Therapeutics, Inc., and Novartis have recently entered into an exclusive global development and commercialization license agreement that aims to advance molecular glue degraders (MGDs), with a particular focus on MRT-6160. This agreement grants Novartis the worldwide rights to develop,

How Will Kapoose Creek Bio's New Acquisition Transform Drug Discovery?
Research & Development How Will Kapoose Creek Bio's New Acquisition Transform Drug Discovery?

Kapoose Creek Bio, a biotechnology firm well-versed in AI-driven natural product drug discovery, has made a significant leap forward with its latest acquisition. The company has secured an exclusive license to the chemical informatics platform of Adapsyn Bioscience and acquired Adapsyn's drug

Loading

Subscribe to our weekly news digest.

Join now and become a part of our fast-growing community.

Invalid Email Address
Thanks for Subscribing!
We'll be sending you our best soon!
Something went wrong, please try again later